passed for press, or provide clear instructions if amendments are required. You are very welcome to email your comments to us at ian.blaza@queensawardsmagazine.com (this is our preferred option) or else you can call us on 01536 520654
2 018 QUEEN’S AWARD MAGAZINE We have produced the following editorial to the best of our understanding of your require- ments, and using the text & materials you have kindly supplied to us. Would you please care
in the Index of Contributors If you have also ordered an enhanced entry to be placed in the Index of Contributors, then a proof of your logo is shown here on the right. Note that, for technical reasons, the size of entry in the printed product may vary slightly from that shown here. This option will also include your full contact details, as used on the editorial entry and proofed below here.
Company Description in the ‘List of Winners’ preceeding the section, for checking: Working with small pharmaceutical and biotechnology companies and universities to support the development of medicines for patient benefit Boyds Renowned for supporting small pharmaceutical and biotechnology companies and medical departments at
universities, BOYDS helps clients across the globe to translate their research ideas into medicines to treat human diseases. Established in 2005 by Professor Alan Boyd, Boyds provides a range of expertise and skills central to the development of pharmaceutical and biotechnology medicinal products. The company started with an o ce in Crewe, Cheshire, and subsequently opened an o ce in Cambridge in 2009. It now has a team of ten full time sta and several associate consultants who work across the whole range of medicines development, including product development, regulatory a airs, manufacturing, toxicology, pharmacovigilance and medical monitoring. The company has extensive experience in developing pharmaceutical and biological products covering multiple treatment approaches. In particular, Boyds specialises in the development and commercialisation of cell and gene therapy products. This also includes rare and orphan disease indications. Boyds’ unique and extensive experience in relation to cell and gene therapy products adds value to the company’s proposition. Professor Boyd has particular expertise in this area and developed the rst gene-based therapy that was submitted to the Medicines Regulatory Authority in Europe for approval. WORKING WITH STARTUPS In attracting new clients, Boyds’ strategy has been to work initially with medical departments in universities that have research ideas for new therapies to treat human disease, and their readiness to take the rst steps along the medicines development pathway. Working with the medical department to outline the steps to be taken, Boyds helps to identify ways to navigate around possible challenges, as well as helping to raise the funding needed to pay for early development work. Boyds then provides support using its expert sta to advise on the manufacture of the product, the pre-clinical assessments, the clinical study activities and the regulatory approvals for the work from the relevant Government health agencies, ensuring that any development work undertaken will be compliant for the eventual marketing of the product in the key markets. Much of this work typically results in the academic institution concerned spinning out a company from the organisation and establishing a stand-alone enterprise. A GLOBAL INDUSTRY The pharmaceutical industry is a global industry and it is no longer possible to develop a
Professor Alan Boyd, CEO and founder of Boyds.
multiple therapeutic areas. These are major markets for pharmaceutical development and commercialisation. Boyds also works for companies and academic institutions that are located in countries that have a strong science and medical base and whose government encourages entrepreneurship to help SME development. Boyds has seen consistent growth in turnover, with over 60% of revenue now coming from overseas clients and anticipates this trend to continue, with the clear vision to continue to use its knowledge and expertise to help clients to develop products for the bene t of patients. BOYDS Cheshire O ce: Electra House, Crewe Business Park, Crewe, Cheshire CW1 6GL Cambridge O ce: Unit M, South Cambridge Business Park, Babraham Road, Sawston, Cambridgeshire CB22 3JH Tel: +44 (0)1270 270010 • info@boydconsultants.com www.boydconsultants.com Z @boydconsultants F Boyds
medicinal product in just one country, mainly due to cost and scale of the work that needs to be undertaken to get a medicine to market. Therefore, to succeed in developing medicines for patient bene t, there is a need to collaborate globally. Boyds actively supports clients in the USA, Canada, Europe, Japan, Australia and Israel who are developing medicinal products across
www. queensawardsmagazine .com
36
lease note that the final layout of this material may vary slighty from that shown here, to suit the final design of the page it is included on. No further proofs will be sent after approval unless requested. This proof is supplied in format and resolution suitable for email; if you require a high-resolution version, or would prefer it in an alternative format - such as a JPG image – then please contact us on ian.blaza@queensawardmagazine.com
Made with FlippingBook Learn more on our blog